磁共振波谱指纹技术探测乳腺癌脂质弛豫时间的初步研究
该前瞻性研究纳入12例活检证实的乳腺癌患者和14例健康对照,在3T磁共振上采用DTI、MRSF和DCE-MRI协议,单次扫描不足20秒即可获得脂质弛豫时间。研究发现多个脂质峰(1.3 ppm、4.1 ppm、5.22 ppm的T1及5.31 ppm的T2)在乳腺癌与正常纤维腺体组织间存在显著差异(p<10⁻³),提示脂质弛豫时间可能作为定量表征乳腺组织的潜在标志物。
要点
- MRSF可在临床可接受的扫描时间内(<20秒)快速获取乳腺脂质弛豫时间。
- 乳腺癌与正常纤维腺体组织在多个脂质峰(1.3、4.1、5.22、5.31 ppm)的弛豫时间存在显著差异。
- 脂质弛豫时间有望成为乳腺组织定量表征的潜在影像标志物,但需进一步验证。
关键影像表现/征象
- 共识别出7个可区分的脂质代谢物峰并记录其弛豫时间。
- 多个脂质共振在对照组与患者间表现出统计学显著变化,其中1.3 ppm、4.1 ppm和5.22 ppm的T1以及5.31 ppm的T2具有强显著性(p<10⁻³)。
诊断标准与关键数值
- 1.3 ppm处T1:乳腺癌为355±17 ms,正常纤维腺体组织为389±27 ms,差异显著(p<10⁻³)。
- 4.1 ppm处T1:乳腺癌为255±86 ms,正常纤维腺体组织为127±33 ms,差异显著(p<10⁻³)。
- 5.22 ppm处T1:乳腺癌为724±81 ms,正常纤维腺体组织为516±62 ms,差异显著(p<10⁻³)。
- 5.31 ppm处T2:乳腺癌为56±5 ms,正常纤维腺体组织为44±3.5 ms,差异显著(p<10⁻³)。
临床应用与阅片要点
- MRSF单个体素采集可在20秒内完成,适合临床流程整合。
- 关注1.3、4.1、5.22 ppm的T1及5.31 ppm的T2差异,可能辅助鉴别乳腺癌与正常纤维腺体组织。
- 目前仅为初步研究,尚不能作为独立诊断工具,需结合常规影像学表现。
局限性
- 样本量小(12例患者和14例对照),统计效能有限。
- 单中心前瞻性研究,结果需外部验证。
- 脂质弛豫时间差异的生物学机制尚未阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the clinical relevance of the relaxation times of lipids within breast cancer and normal fibroglandular tissue in vivo, using magnetic resonance spectroscopic fingerprinting (MRSF).
METHODS: Twelve patients with biopsy-confirmed breast cancer and 14 healthy controls were prospectively scanned at 3 T using a protocol consisting of diffusion tensor imaging (DTI), MRSF, and dynamic contrast-enhanced (DCE) MRI. Single-voxel MRSF data was recorded from the tumor (patients) - identified using DTI - or normal fibroglandular tissue (controls), in under 20 s. MRSF data was analyzed using in-house software. Linear mixed model analysis was used to compare the relaxation times of lipids in breast cancer VOIs vs. normal fibroglandular tissue.
RESULTS: Seven distinguished lipid metabolite peaks were identified and their relaxation times were recorded. Of them, several exhibited statistically significant changes between controls and patients, with strong significance (p < 10-3) recorded for several of the lipid resonances at 1.3 ppm (T1 = 355 ± 17 ms vs. 389 ± 27 ms), 4.1 ppm (T1 = 255 ± 86 ms vs. 127 ± 33 ms), 5.22 ppm (T1 = 724 ± 81 ms vs. 516 ± 62 ms), and 5.31 ppm (T2 = 56 ± 5 ms vs. 44 ± 3.5 ms, respectively).
CONCLUSIONS: The application of MRSF to breast cancer imaging is feasible and achievable in clinically relevant scan time. Further studies are required to verify and comprehend the underling biological mechanism behind the differences in lipid relaxation times in cancer and normal fibroglandular tissue.
KEY POINTS: •The relaxation times of lipids in breast tissue are potential markers for quantitative characterization of the normal fibroglandular tissue and cancer. •Lipid relaxation times can be acquired rapidly in a clinically relevant manner using a single-voxel technique, termed MRSF. •Relaxation times of T1 at 1.3 ppm, 4.1 ppm, and 5.22 ppm, as well as of T2 at 5.31 ppm, were significantly different between measurements within breast cancer and the normal fibroglandular tissue.
引用
- Nissan, Kulpanovich, Agassi, et al. Probing lipids relaxation times in breast cancer using magnetic resonance spectroscopic fingerprinting. Eur Radiol. 2023. PMID: 36976338. doi:10.1007/s00330-023-09560-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。